Insys Therapeutics Reports Record Third Quarter 2015 Results

Go back to Insys Therapeutics Reports Record Third Quarter 2015 Results

Subsys Pushes Insys Therapeutics (INSY) to 3Q Beat; Piper Jaffray Reiterates Overweight

November 6, 2015 9:57 AM EST

Piper Jaffray reiterated an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and raised the price target to $49.00 (from $48.00), following the company's 3Q15 earnings report. Insys reported 3Q15 EPS of $0.50, on revenues of $91M, well ahead of Street estimates. Subsys once again showed strong sequential growth, with sequential sales growth of 19% over 2Q15. Management suggested... More

Insys Therapeutics (INSY) Tops Q3 EPS by 27c

November 5, 2015 8:00 AM EST

Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of $0.50, $0.27 better than the analyst estimate of $0.23. Revenue for the quarter came in at $91.3 million versus the consensus estimate of $82.98 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

... More

Insys Therapeutics (INSY) CEO Babich Steps Down

November 5, 2015 6:59 AM EST

Insys Therapeutics, Inc. (NASDAQ: INSY) announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will continue to serve of the Chairman of the Companys Board of Directors. Daniel Brennan has been appointed Executive Vice President and Chief Operating Officer effective November 1, 2015.

It has been a privilege to lead Insys for the past six... More